Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA)
Q1 2012 Earnings Call
May 09, 2012 8:30 am ET
Executives
Kevin Mannix - Director of Investor Relations - Teva North AmericaShlomo Yanai - Chief Executive Officer and PresidentEyal Desheh - Chief Financial OfficerJeremy Levin - William S. Marth - Chief Executive Officer of Teva Americas and President of Teva AmericasRobert Koremans - Michael Hayden - Unknown Executive - Gerard W.M. Van Odijk - Former Chief Executive Officer of Teva Europe and President of Teva EuropeAnalystsChristopher Schott - JP Morgan Chase & Co, Research DivisionAaron Gal - Sanford C. Bernstein & Co., LLC., Research DivisionTraver A. Davis - Piper Jaffray Companies, Research DivisionCorey B. Davis - Jefferies & Company, Inc., Research DivisionDavid G. Buck - The Buckingham Research Group IncorporatedGregory B. Gilbert - BofA Merrill Lynch, Research DivisionLimor Gruber - Psagot Investment House Ltd., Research DivisionFrank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research DivisionElliot Wilbur - Needham & Company, LLC, Research DivisionDouglas D. Tsao - Barclays Capital, Research DivisionMarc Goodman - UBS Investment Bank, Research DivisionFlorent Cespedes - Exane BNP Paribas, Research DivisionJason M. Gerberry - Leerink Swann LLC, Research DivisionShibani Malhotra - RBC Capital Markets, LLC, Research DivisionPresentationOperatorPrevious Statements by TEVA
» Teva's CEO Presents at Barclays Capital Global Healthcare Conference (Transcript)
» Teva Pharmaceutical Industries' Management Presents at Citi Global Health Care Conference (Transcript)
» Teva Pharmaceutical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
